Post-traumatic stress disorder affects nearly 8 million adults in the United States each year, and the two medications with FDA approval for its treatment — sertraline and paroxetine — help fewer than half the patients who try them achieve remission. For the millions of people whose PTSD persists despite standard pharmacotherapy and psychotherapy, the clinical literature has increasingly pointed toward ketamine as an intervention that can interrupt the neurological architecture of trauma response in ways that conventional treatments cannot reach. At Infuse RVA in South Chesterfield, our team evaluates and treats patients from across the greater Richmond area whose PTSD has created a treatment stalemate — and IV ketamine infusion therapy is an important part of what we can offer.
Understanding PTSD at the Neurological Level
Post-traumatic stress disorder is not simply a psychological response to difficult events — it is a disorder of fear memory consolidation and threat appraisal that involves measurable changes in the structure and function of brain regions including the amygdala, hippocampus, and prefrontal cortex. In PTSD, the amygdala — the brain’s threat-detection center — becomes hyperactive, while the prefrontal cortex — which provides regulatory control over threat responses — becomes relatively less effective at dampening that hyperactivity. This imbalance produces the hallmark features of PTSD: hypervigilance, intrusive memories, emotional dysregulation, and avoidance behaviors that progressively narrow a person’s world.
How Ketamine Targets the Neurology of Trauma
Ketamine’s relevance to PTSD is tied to its mechanism at NMDA receptors, which play a central role in the synaptic plasticity processes underlying fear memory formation and extinction. Research at institutions including Yale University and the National Institute of Mental Health has demonstrated that ketamine can both reduce the emotional intensity of traumatic memories and facilitate the formation of new, corrective associations — essentially creating the neurological conditions under which the brain can begin to update its threat-response circuitry. These effects have been documented to occur within hours of a single infusion in some patients, a time course that no standard PTSD medication approaches. Ketamine for PTSD is an off-label application, meaning it is not FDA-approved for this specific indication, but it is administered on the basis of a growing body of clinical evidence that our team follows closely.
The Evaluation Process at Infuse RVA
At Infuse RVA, our evaluation process for PTSD patients begins with a thorough clinical review that addresses the full spectrum of their presentation: the nature and duration of the traumatic exposure, prior treatment attempts and responses, current comorbidities (depression, anxiety disorders, and substance use frequently co-occur with PTSD), and current medications. We do not recommend IV ketamine as a first step for patients who have not yet received evidence-based PTSD treatments such as prolonged exposure therapy or cognitive processing therapy — but for patients who have completed those treatments without achieving remission, or for whom the severity of symptoms has prevented them from engaging with trauma-focused psychotherapy at all, ketamine presents a genuinely different biological pathway worth exploring. Many of the barriers that keep patients stuck in PTSD recovery are rooted in those very treatment gaps that conventional approaches fail to bridge.
Ketamine, Neuroplasticity, and the Role of Psychotherapy
One aspect of ketamine’s application in PTSD that we discuss with every patient is the relationship between ketamine’s acute neuroplasticity window and the potential benefit of concurrent psychotherapeutic work. Several clinical protocols have explored the combination of ketamine infusions with structured psychotherapy during the post-infusion period, when the brain’s plasticity is temporarily enhanced and resistance to psychological work may be reduced. At Infuse RVA, we work with patients to coordinate their broader care team — including any therapists or psychologists they are working with — so that the neurological opening created by ketamine can be utilized therapeutically rather than left untapped. We do not provide ketamine-assisted psychotherapy ourselves, but we take the coordination of care seriously.
Addressing Barriers to Treatment
One barrier to ketamine treatment for PTSD in the Richmond area is the persistent narrative that PTSD can only be treated with exposure therapy and that medication-based approaches are a crutch rather than a treatment. This framing does real harm to patients who, for any number of legitimate reasons — severity of symptoms, prior trauma with therapy, specific trauma characteristics — are not able to engage productively with exposure-based approaches at a given moment in their treatment. Ketamine does not replace psychotherapy for PTSD; it may, for some patients, create the neurological preconditions that make psychotherapy possible. We discuss this nuance openly with every patient we evaluate.
A second barrier is the stigma that still surrounds ketamine in the general culture, particularly for patients in the Richmond and South Chesterfield community who associate it with recreational drug use. We acknowledge that history directly and contextually: clinical ketamine administration for psychiatric indications is conducted in a medical facility under monitoring by trained clinicians, at doses and protocols that differ fundamentally from recreational use, in a population of patients who have been carefully evaluated for candidacy and contraindications. The cultural history of a molecule does not determine its clinical utility, and our team approaches every patient conversation about ketamine’s reputation with patience and factual clarity. Results vary by individual, and we encourage you to explore your options by discussing your complete history with our team. It is also worth understanding the connection between PTSD and chronic pain, as many patients present with both conditions — and ketamine’s mechanism addresses neurological pathways relevant to each.
Frequently Asked Questions
Is Ketamine FDA-Approved for PTSD?
No. Ketamine for PTSD is an off-label application — it is not FDA-approved for this specific indication. However, off-label use is legally and ethically appropriate when supported by clinical evidence and administered with informed consent. Our team will explain the relevant research and your specific candidacy before recommending ketamine for PTSD.
How Quickly Does Ketamine Work for PTSD Symptoms?
Some patients experience meaningful reductions in hypervigilance, intrusive thoughts, and anxiety within hours of their first infusion. The timeline and magnitude of response vary widely by individual, and we do not make guarantees about outcomes. A realistic discussion of your expected response is part of every evaluation at Infuse RVA.
How Many IV Ketamine Infusions Are Typically Needed for PTSD?
Most patients receive a series of four to six infusions over two to three weeks for the initial course, followed by maintenance infusions as needed based on response. PTSD patients often benefit from longer-term engagement with our practice to monitor for symptom recurrence and determine when booster infusions are appropriate.
Can I Continue My PTSD Medications While Receiving Ketamine?
In most cases, yes — though certain medications may require dose adjustments or temporary modifications to avoid interactions. Our team reviews your complete medication list before beginning treatment and coordinates with your other providers as needed. Do not make changes to your current medications without discussing them with our team first.
Does Infuse RVA Work with Patients Who Are Also in PTSD Therapy?
Yes, and we actively encourage coordination with therapists and other mental health providers. We take the clinical context of ketamine treatment seriously and work to ensure that what we offer is integrated into your broader care rather than siloed from it. Bring us the name and contact of any providers you are working with, and we will facilitate communication where appropriate.
Key Takeaways
- PTSD involves measurable neurological changes in the amygdala, hippocampus, and prefrontal cortex that standard antidepressants address only partially.
- Ketamine works through NMDA receptor blockade to interrupt fear memory circuitry and promote neuroplasticity — an off-label application supported by growing clinical research.
- At Infuse RVA, we evaluate PTSD patients thoroughly before recommending ketamine, including a review of prior treatment history and current comorbidities.
- Coordination with existing therapists and providers is a priority in our clinical approach.
- Results vary by individual; discuss your complete history with our team to determine if IV ketamine is appropriate for your situation.
Conclusion
PTSD that has outlasted standard treatment is not a personal failure — it is a clinical signal that the biological substrate of your fear response has not yet been adequately addressed. At Infuse RVA in South Chesterfield, our team approaches every PTSD patient with the same commitment: to understand your full picture, evaluate all relevant options honestly, and recommend only what we believe can genuinely help. If you are in the greater Richmond area and your PTSD has not responded to prior treatment, we invite you to schedule a consultation with our South Chesterfield office today.
References
National Center for PTSD, U.S. Department of Veterans Affairs. PTSD Treatment Basics. https://www.ptsd.va.gov/understand_tx/tx_basics.asp
National Institute of Mental Health. Post-Traumatic Stress Disorder. https://www.nimh.nih.gov/health/topics/post-traumatic-stress-disorder-ptsd
Yale School of Medicine. Ketamine’s Rapid Antidepressant Effects. https://medicine.yale.edu/news/yale-medicine-magazine/article/rapid-antidepressant-effects/
American Psychiatric Association. What Is PTSD? https://www.psychiatry.org/patients-families/ptsd/what-is-ptsd
About Infuse RVA Team
At InfuseRVA Ketamine & Wellness in South Chesterfield, VA, our team works specifically with patients in the greater Richmond area who have not found adequate relief through conventional treatment — those whose depression, PTSD, anxiety, or chronic pain persists despite prior medication and therapy trials. We evaluate each patient individually before recommending any treatment approach, with IV ketamine infusion therapy and SPRAVATO® (esketamine) available for patients who meet criteria for treatment-resistant depression following a thorough clinical review. Our care is built around both the physical and emotional dimensions of mental health: we take the whole patient seriously, from unexplained physical symptoms to the longer history that brought them to our door.
Medical Disclaimer
This content is provided by Infuse RVA for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. IV ketamine for PTSD is an off-label use of an approved medication. Only a qualified medical provider can determine whether ketamine therapy is appropriate for your specific situation. Results vary by individual, and no outcomes are guaranteed. Please discuss all treatment options with your provider before making any decisions about your care.
